Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are AAV transfer cassettes and plasmids used in the production of recombinant adeno-associated viral (rAAV) vectors. The disclosed cassettes and plasmids comprise one or more transgenes having therapeutic efficacy in the amelioration, treatment and/or prevention of one or more diseases or disorders, such as Niemann-Pick Disease, type C1 (NPC1).
Core Innovation
The disclosed invention relates to AAV transfer cassettes and recombinant AAV vectors for gene therapy of Niemann-Pick Disease type C1 (NPC1). The nucleic acid is encapsidated by a protein capsid, and the transfer cassette architecture includes 5′ and 3′ ITRs, a promoter, an NPC1 transgene, and a polyadenylation signal.
The described transfer cassette specification includes promoter/enhancer options, ITR length/origins, intronic sequence options, polyadenylation signal options, and NPC1 sequence variants, including human NPC1 and SEQ ID variants. The disclosed cassette variants include optional truncations/mutations of the NPC1 sequence as part of the specified nucleic acid content.
The recombinant AAV vectors are used to treat a subject having Niemann-Pick Disease type C1 (NPC1), including systemically administering the recombinant AAV vector. The document reports that treatment reduces cholesterol accumulation in cells transduced by the recombinant AAV vector.
Claims Coverage
The independent claims cover two closely related treatment methods for NPC1 using recombinant AAV vectors with an AAV9 capsid and specified transfer cassette sequence(s). Across the independent claims, the inventive features include systemically administering an AAV vector, using an AAV9 capsid protein subunit, specifying transfer cassette sequence content (SEQ ID NO:14 in one claim; SEQ ID NOS:15–19 in the other), and requiring that treatment reduces cholesterol accumulation in transduced cells.
Systemic administration of recombinant AAV vector for NPC1
A method for treating a subject having Niemann-Pick Disease Type C1 (NPC1) in need thereof comprising systemically administering to the subject a recombinant AAV vector comprising a protein capsid and a nucleic acid encapsidated by the protein capsid.
NPC1 treatment with AAV9 capsid and SEQ ID NO:14 transfer cassette
The method wherein the nucleic acid comprises a transfer cassette comprising the sequence of SEQ ID NO: 14 and the protein capsid comprises a capsid protein subunit from an AAV9 serotype.
Reduction of cholesterol accumulation in transduced cells
The method wherein treatment reduces cholesterol accumulation in cells of the subject transduced by the recombinant AAV vector.
NPC1 treatment with AAV9 capsid and SEQ ID NOS:15-19 transfer cassette
A method for treating a subject having Neimann-Pick Disease Type C1 (NPC1) in need thereof comprising systemically administering to the subject a recombinant AAV vector wherein the nucleic acid comprises a transfer cassette comprising the sequence of any one of SEQ ID NOS: 15-19 and the protein capsid comprises a capsid protein subunit from an AAV9 serotype.
Overall, the claim coverage centers on systemic administration of an AAV vector that includes an AAV9 capsid protein subunit and an encapsidated NPC1 transfer cassette defined by SEQ ID NO:14 or by any one of SEQ ID NOS:15–19, with the treatment limitation that it reduces cholesterol accumulation in cells transduced by the recombinant AAV vector.
Stated Advantages
Treatment reduces cholesterol accumulation in cells transduced by the recombinant AAV vector.
Documented Applications
In vitro rescue of NPC1 lysosomal/cholesterol phenotypes using AAV2-hNPC1, including LysoTracker and filipin assays.
In vivo partial phenotypic rescue and survival benefit in NPC1−/− mice using AAV9-hNPC1, including Kaplan-Meier survival and behavioral testing.
Interested in licensing this patent?